ClinicalTrials.Veeva

Menu

Mg Induced Changes From Day 0 to Day 28 on Serum and Urine Bone Metabolic Parameters in 70 y Old Females (no 50). (parathormon)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status and phase

Completed
Phase 1

Conditions

Unspecified Disorder of Bone Density and Structure

Treatments

Dietary Supplement: Oral magnesium substitution
Dietary Supplement: Placebo tablets without magnesium

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02549521
Nycomed contract 06.09.05 (Other Grant/Funding Number)
Etical commitee, 548-05-99010 (Other Identifier)
Nycomed 06.09.05
Data inspectorate 13433 (Registry Identifier)

Details and patient eligibility

About

Calcium and vitamin D substitution has for a long time been used to improve osteoporosis.The main storage place for magnesium is in the bone. Magnesium is direct under calcium in the periodic system making it possible to interact with the crystal structure. Some small studies have shown beneficial effects of magnesium substitution on osteoporosis. Evidence has shown improvement with calcium, alcohol, fruit and vegetable nutrients on bone loss. It has been uncertain however, which of these factors can contribute to such a change. The effect of magnesium substitution 240 mg daily as therefore studied in two parallel groups where both received calcium carbonate 1000 mg/day and cholecalciferol 10 ug/day, one got placebo and the other received magnesium. This was studied on various expressions for bone metabolism after zero, seven and 28 days in elderly females aged 70 years old.

Full description

Elderly 70 year old ladies who had been to an outpatient X-ray investigation were invited to participate in this study. They were all healthy without any signs of osteoporosis, or fractures.They were stimulated to participate by having done bone density measurements free. Patients who had used biphosphonates, oestrogens, glucocorticoids , diuretics, immunomodulating agents, or prolonged use of heparin were excluded.

Patients with possible secondary osteoporosis due to primary hyperthyroidism or chronic lung disease were also excluded. The participants were randomized into placebo or Mg-treatment groups. They were seen by the dietician, and blood and urine samples were taken at day 0, 7 and 28 at the same time these days. Medicine was prepacked for intake twice daily. They received medicine for 30 days and should only take for 28 days. The number of tablets which should be left was controlled the last day. The participants were informed about the results of the bone density measurements taken the first and the last day. All the patient contacts were undertaken by the same dietician.

Enrollment

50 patients

Sex

Female

Ages

70 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Homeliving healthy female volunteers aged 70 years old were recruited by phone.

Exclusion criteria

Persons who had used:

  • biphosphonates,

  • oestrogens,

  • glucocortocoids,

  • antiepileptic drugs,

  • diuretics,

  • immunmodulating agents,

  • prolonged usage of heparin.

  • patients with possible secondary osteoporosis and

  • diagnosis as:

    • inflammatory bowel disease,
    • primary hyperthyroidisms,
    • chronic obstructive lung disease

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

50 participants in 2 patient groups, including a placebo group

Oral magnesium substitution
Active Comparator group
Description:
Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
Treatment:
Dietary Supplement: Oral magnesium substitution
Magnesium + or Magnesium -
Placebo Comparator group
Description:
Placebo tablets without magnesium.
Treatment:
Dietary Supplement: Placebo tablets without magnesium

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems